Spectrum Of Activity
HIV infection 200 mg PO q12hNo renal dose adjustment
Safety and efficacy in pediatric patients <6 years of age or <16 kg of BW have not been established
BW: 16-20 kg: 100 mg PO q12h
BW: 20-25 kg: 125 mg PO q12h
BW: 25-30 kg: 150 mg PO q12h
BW: >30 kg: 200 mg PO q12hNo renal dose adjustment
Mild or moderate hepatic impairment No dose adjustment
Severe hepatic impairment No data
HIV infection, Treatment-experienced patients
Monitor viral load prior to initiation or modification of treatment.
Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.
Monitor hepatitis B screening.
Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.
Monitor ALT,AST, and total bilirubin, basic chemistry including serum sodium, potassium, bicarbonate, chloride, BUN, creatinine, and creatinine-based estimated glomerular filtration rate.
Toxic epidermal necrolysis
Drug reaction with eosinophilia and systemic symptoms
Immune reconstitution syndrome
Multiple drug-drug interactions
Antimicrobial class: Antiretroviral, Non-nucleoside reverse transcriptase inhibitor
Pregnancy category: B
Average serum half life: 9.05 - 41 hours
Urine penetration: Therapeutic
CSF penetration: Therapeutic
Precautions: Immune reconstitution syndrome has been reported with combination ARV therapy; patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections.
Discontinue immediately and monitoring recommended if hypersensitivity reactions or severe rash occurs.